Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Merck
Express Scripts
AstraZeneca
Colorcon

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Latanoprost; netarsudil dimesylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for latanoprost; netarsudil dimesylate and what is the scope of patent protection?

Latanoprost; netarsudil dimesylate is the generic ingredient in one branded drug marketed by Aerie Pharms Inc and is included in one NDA. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost; netarsudil dimesylate has forty-three patent family members in seven countries.

There are twenty drug master file entries for latanoprost; netarsudil dimesylate. One supplier is listed for this compound.

Summary for latanoprost; netarsudil dimesylate
International Patents:43
US Patents:7
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 20
Suppliers / Packagers: 1
DailyMed Link:latanoprost; netarsudil dimesylate at DailyMed
Pharmacology for latanoprost; netarsudil dimesylate

US Patents and Regulatory Information for latanoprost; netarsudil dimesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Aerie Pharms Inc ROCKLATAN latanoprost; netarsudil dimesylate SOLUTION/DROPS;OPHTHALMIC 208259-001 Mar 12, 2019 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for latanoprost; netarsudil dimesylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0364417 97C0128 France   Start Trial PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
McKinsey
Harvard Business School
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.